Waters Corporation
$ 406.86
1.79%
07 Aug - close price
- Market Cap 39,947,895,000 USD
- Current Price $ 406.86
- High / Low $ 407.88 / 397.09
- Stock P/E 102.74
- Book Value 155.78
- EPS 3.96
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.02 %
- 52 Week High 414.15
- 52 Week Low 278.49
About
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Analyst Target Price
$433.39
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-09 | 2025-11-04 | 2025-08-04 | 2025-05-06 | 2025-02-12 | 2024-11-01 | 2024-07-31 | 2024-05-07 | 2024-02-06 | 2023-11-07 |
| Reported EPS | 3.05 | 2.7 | 4.53 | 3.4 | 2.95 | 2.25 | 4.1 | 2.93 | 2.63 | 2.21 | 3.62 | 2.84 |
| Estimated EPS | 3.01 | 2.31 | 4.51 | 3.22 | 2.94 | 2.22 | 4.03 | 2.68 | 2.56 | 2.09 | 3.55 | 2.55 |
| Surprise | 0.04 | 0.39 | 0.02 | 0.18 | 0.01 | 0.03 | 0.07 | 0.25 | 0.07 | 0.12 | 0.07 | 0.29 |
| Surprise Percentage | 1.3289% | 16.8831% | 0.4435% | 5.5901% | 0.3401% | 1.3514% | 1.737% | 9.3284% | 2.7344% | 5.7416% | 1.9718% | 11.3725% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WAT
2026-08-08 12:13:09
A director at Waters Corp (NASDAQ:WAT), Christopher A. Kuebler, sold 3,626 shares of the company's common stock for $1.44 million. This transaction occurred after he acquired the same number of shares through the exercise of stock options. Following these transactions, Kuebler directly holds 17,808 shares.
2026-08-08 11:39:28
Waters Corp director Christopher A. Kuebler sold 3,626 shares of company stock for $1.44 million after exercising stock options. This transaction increased his direct holdings to 17,808 shares. The sale occurred as Waters Corp shares traded near a 52-week high, with the company recently reporting strong Q2 2026 earnings and receiving an analyst upgrade.
2026-08-08 11:39:28
A director at Waters Corp, Christopher A. Kuebler, sold 3,626 shares of company stock for $1.44 million after exercising stock options. Following the transaction, Kuebler directly holds 17,808 shares. The sale occurred as Waters Corp shares are trading near their 52-week high, and the company recently reported strong Q2 2026 earnings that surpassed analyst expectations.
2026-08-07 21:09:01
Waters Corp. (WAT) shares advanced 1.79% on Friday, closing at $406.86, despite underperforming its competitors. The company's stock finished 1.76% below its 52-week high of $414.15. The broader market also saw gains, with the S&P 500 Index rising 0.62% and the Dow Jones Industrial Average rising 0.28%.
2026-08-07 05:39:10
This article provides analyst insights, price targets, and recommendations for Waters Corp (WAZ.DU), highlighting recent upgrades and downgrades from various financial institutions. It shows that TD Cowen upgraded the stock from Hold to Buy, while other firms like RBC Capital, Evercore ISI Group, Wells Fargo, Barclays, and Goldman Sachs maintained their previous ratings. The stock's current price and daily change are also presented.
2026-08-06 20:37:23
Becton, Dickinson and Company (BDX) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. Key highlights include the completion of the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation, generating a $4 billion cash distribution used for share repurchases and debt repayment. The company reported worldwide revenues of $4.983 billion for the quarter, a 5.4% increase from the prior-year period, driven by strong performance in its Medical Essentials, Connected Care, BioPharma Systems, and Interventional segments. However, the company continues to address unresolved FDA Warning Letters for its El Paso manufacturing facility and Dispensing quality management system, which could impact operations and liabilities.
